DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double attack on lymphoma: CAR-T cells then new drugs
Disease control Recruiting nowThis study is testing whether adding experimental drugs after CAR-T cell therapy can help control lymphoma that has returned or hasn't responded to previous treatments. The research involves 42 adults with large B-cell lymphoma who have already received CAR-T therapy. Participant…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Apr 01, 2026 14:51 UTC
-
New hope for Tough-to-Treat lymphoma: targeted drug trial seeks better results
Disease control Recruiting nowThis study is testing whether adding the targeted drug zanubrutinib to standard chemotherapy (R-CHOP) works better for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who have specific genetic markers. The trial will enroll about 21 adu…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug trial offers hope for Tough-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study is testing an experimental drug called MDX2003 for people with several types of B-cell lymphoma that have come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. It will…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: ModeX Therapeutics, An OPKO Health Company • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Engineered immune cells battle aggressive cancer in new trial
Disease control Recruiting nowThis study is testing a personalized cell therapy for adults with a fast-growing type of lymphoma that has come back or hasn't responded to at least two prior treatments. Doctors will collect a patient's own immune cells, genetically modify them to better target the cancer, and i…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Mar 27, 2026 12:41 UTC
-
Scientists test 'Ready-Made' cell therapy for Tough-to-Treat blood cancers
Disease control Recruiting nowThis is an early-stage safety study testing a new type of cell therapy called P-CD19CD20-ALLO1 for adults with aggressive B-cell lymphomas that have come back or not responded to standard treatments. The therapy uses genetically modified immune cells from a donor (not the patient…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
Scientists tweak cancer treatment recipe to boost powerful cell therapy
Disease control Recruiting nowThis early-stage study aims to find the best way to prepare a patient's body before they receive a powerful cell therapy called CAR-T. Researchers are testing different combinations of chemotherapy and low-dose radiation in about 40 adults with a type of aggressive lymphoma that …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for tough lymphomas: first human trial begins
Disease control Recruiting nowThis is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has returned or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also c…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
New hope for Tough-to-Treat blood cancer: trial tests powerful drug trio
Disease control Recruiting nowThis study is testing a new combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to previous treatments. The goal is to see if …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New 'Living Drug' trial offers hope for lymphoma patients out of options
Disease control Recruiting nowThis is a first-in-human study testing the safety and early effectiveness of a new cell therapy called SynKIR-310. It is for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments, including other CAR-T therapies. The main goa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Shielding hearts from Chemo's hidden danger
Prevention Recruiting nowThis study aims to prevent heart damage in patients receiving chemotherapy for a common type of lymphoma. Researchers are testing whether giving a drug called dexrazoxane before each chemotherapy session can protect the heart muscle. The trial will involve 324 adults with diffuse…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC
-
Spinal fluid test could spot hidden brain cancer risk in lymphoma patients
Knowledge-focused Recruiting nowThis study is testing a new method to find early signs that aggressive B-cell lymphoma might spread to the brain and spinal cord (central nervous system). Researchers will analyze spinal fluid from 50 high-risk patients using a sensitive DNA test to see if it can detect cancer ce…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Can better Doctor-Patient talks improve lymphoma care?
Knowledge-focused Recruiting nowThis study is testing a new training program called Hematolo-GIST, designed to help lymphoma doctors communicate more effectively with their patients. It involves 48 doctors and their patients with a specific type of aggressive lymphoma. The main goal is to see if the training is…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:01 UTC